Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.0952W HIGH $22.38
Volume
963.56 K
Value Traded
18.93 M
Short % Float
16.61%
-9.54%Week
-40.55%1 Month
-37.63%3 Month
-43.76%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
125.20 M
EPS (TTM)
-9.31
P/E Ratio
-
Ent. Value
-51.03 M
Total Shares
17.15 M
Float Shares
17.09 M
Insiders
0.36%
Institutions
55.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TNXP Catalyst Timeline
Dated clinical, regulatory and corporate events for Tonix Pharmaceuticals Holding Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tonix Pharmaceuticals Holding Corp.
1685Total events
34Upcoming
355Tier-1 (high impact)
2014 to 2034Coverage
Upcoming catalysts 2
Event history 50
▲Reimbursement / PricingTNX-102 SL (Tonmya)ApprovedPost-Market
Second major managed Medicare payer agreement for TONMYA effective immediately, adding ~21M Medicare lives
fibromyalgiasource ↗
▲Management ChangeCorporate
Thomas Englese promoted to Chief Commercial Officer, effective immediately
▲Type C MeetingTNX-4800FDA Meeting
Type C FDA meeting minutes received
Lyme disease preventionsource ↗
●PublicationPresentation
Publication in Journal of Virology assessing virulence of 2022 mpox outbreak strain in new animal models
mpoxsource ↗
▲Preclinical PoCTNX-801Preclinical
Identification of three new murine models for mpox infection and pathogenesis
mpox and smallpoxsource ↗
▲Type C MeetingTNX-4800FDA Meeting
Received final minutes from Type C meeting with FDA for TNX-4800
prevention of Lyme diseasesource ↗
▲Quarterly UpdateTNX-102 SL (Tonmya)ApprovedCorporate
Sales force expansion: deploy 50 new representatives by mid-Q3 2026
fibromyalgiasource ↗
◆Trial InitiationTNX-1500Trial
Phase 2 investigator-initiated study expected to initiate
kidney transplant rejectionsource ↗
●Other Regulator MilestoneTNX-1500Ex-US Regulatory
WHO included mosdaprubart as proposed INN for TNX-1500
●PublicationTNX-801Presentation
New paper in Journal of Virology describing murine models for mpox
mpoxsource ↗
▲FDA Feedback ReceivedTNX-4800FDA Meeting
Received final minutes from Type C meeting with FDA for TNX-4800
prevention of Lyme diseasesource ↗
●Quarterly UpdateCorporate
Cash and cash equivalents approximately $176.2 million as of June 30, 2026
▲First Patient DosedTNX-102 SL (Tonmya)ApprovedTrial
First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD
major depressive disordersource ↗
◆R&D DayPresentation
Tonix management to participate in 1x1 meetings at BTIG Infectious Disease Day 2026
▲Product LaunchTNX-102 SL (Tonmya)ApprovedPost-Market
TONMYA commercial launch with GPO coverage expansion
fibromyalgiasource ↗
◆Trial InitiationTNX-102 SL (Tonmya)ApprovedTrial
Expected to initiate enrollment in HORIZON Phase 2 study
major depressive disordersource ↗
▲First Patient DosedTNX-102 SL (Tonmya)ApprovedTrial
First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD
major depressive disorder (MDD)source ↗
●Oral PresentationTNX-1700Presentation
Presented preclinical data at JCA-AACR conference
gastric cancersource ↗
▲Partnership / LicenseTNX-102 SL (Tonmya)ApprovedCorporate
Commercial payer agreements with two leading GPOs
fibromyalgiasource ↗
●Poster PresentationTNX-102 SL (Tonmya)ApprovedPresentation
Poster presentation of retrospective claims analysis of opioid use in fibromyalgia at ASCP 2026
Fibromyalgiasource ↗
▲Full ResultsTNX-1500Clinical Data
Publication of Phase 1 clinical data of TNX-1500 in Journal of Clinical Immunology
prevention of kidney transplant rejectionsource ↗
◆Poster PresentationPresentation
Poster presentation at ISPOR 2026: Characterizing Patients with Fibromyalgia: A U.S. Real-World Claims Analysis
Fibromyalgiasource ↗
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference Fireside Chat
●Poster PresentationTNX-102 SL (Tonmya)ApprovedPresentation
Poster presentation of real-world claims analysis characterizing fibromyalgia patients at ISPOR 2026
Fibromyalgiasource ↗
▲Product LaunchTNX-102 SL (Tonmya)ApprovedPost-Market
First commercial coverage agreement for TONMYA
fibromyalgiasource ↗
▲Partnership / LicenseTNX-102 SL (Tonmya)ApprovedCorporate
Commercial payer agreements with two leading GPOs
fibromyalgiasource ↗
▼Equity OfferingCorporate
Raised $22.6 million proceeds using ATM facility subsequent to quarter-end
●PublicationTNX-1500Presentation
Publication of Phase 1 clinical data for TNX-1500 in Journal of Clinical Immunology
kidney transplant rejectionsource ↗
●Poster PresentationTNX-4800Presentation
Presentation of Phase 1 data and plans for adaptive Phase 2 field study at 4th Annual Ticks and Tickborne Diseases Symposium
Prevention of Lyme Diseasesource ↗
▲Patent GrantedTNX-4800IP / Competition
Issued US Patent 10,457,721 licensed from UMass Chan with expiry January 2036
Prevention of Lyme Diseasesource ↗
◆Poster PresentationTNX-1700Presentation
Poster on pharmacokinetics of TNX-1700 in non-human primates and transgenic mice at AACR 2026
gastric and colorectal cancersource ↗
◆Oral PresentationPresentation
TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression
gastric cancersource ↗
◆Poster PresentationPresentation
In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies
cancer (immune checkpoint)source ↗
●Oral PresentationTNX-1700Presentation
Oral presentation on TFF2 deficiency and aging-associated gastric tumor progression at AACR 2026
gastric cancersource ↗
●Poster PresentationTNX-1700Presentation
Poster presentation on pharmacokinetics of TNX-1700 in non-human primates and transgenic mice at AACR 2026
gastric cancersource ↗
●Poster PresentationTNX-4700Presentation
Poster presentation on in vitro characterization of anti-BTLA monoclonal antibodies at AACR 2026
cancer (multiple)source ↗
●PublicationTNX-102 SL (Tonmya)ApprovedPresentation
Publication of steady-state PK study of TONMYA in Clinical Pharmacology in Drug Development
fibromyalgiasource ↗
◆IND ClearanceTNX-1500IND
FDA clearance of MGH's IND for Phase 2 study expected before trial initiation
prevention of kidney transplant rejectionsource ↗
◆Oral PresentationTNX-801Presentation
Oral presentation on horsepox as modular antigen-delivery system at World Vaccine Congress Washington 2026
Smallpox and mpoxsource ↗
◆Trial InitiationTNX-102 SL (Tonmya)ApprovedTrial
Plan to initiate enrollment in Phase 2 HORIZON study in mid-2026
major depressive disordersource ↗
◆Topline ReadoutTNX-102 SL (Tonmya)ApprovedClinical Data
Topline results expected from Phase 2 OASIS study
Acute Stress Reactionsource ↗
▲Partnership / LicenseTNX-102 SL (Tonmya)ApprovedCorporate
Two prior commercial coverage agreements with leading GPOs effective Q2 2026
fibromyalgiasource ↗
●Oral PresentationTNX-4800Presentation
Presented Phase 1 data and announced plans for Phase 2 field study at Ticks and Tickborne Diseases Symposium
prevention of Lyme diseasesource ↗
●Oral PresentationTNX-102 SL (Tonmya)ApprovedPresentation
Presented data at EULAR 2026, ASCP 2026, and ISPOR 2026
fibromyalgiasource ↗
●PublicationTNX-102 SL (Tonmya)ApprovedPresentation
Published manuscript in Clinical Pharmacology in Drug Development
fibromyalgiasource ↗
▲Quarterly UpdateTNX-102 SL (Tonmya)ApprovedCorporate
Net sales of TONMYA approximately $11 million in Q2 2026
fibromyalgiasource ↗
Past FDA Catalysts and PDUFA Decisions
How TNXP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-22 | TNX-1700 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$119M
Pipeline Value
$29M
Commercial Value
Fair Value
Valuation Signal
6
Drugs Scored
1.2x
rNPV / MCap
Top 40%
Micro Cap(rank 265 of 660)
Percentile Rank
Tonix Pharmaceuticals Holding Corp. carries a moderate pipeline score (40/100), with $1.3B risk-adjusted pipeline value, led by Oxytocin in Pain (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $29.1M x 1.0 = $29M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| TONMYA | $16M | - | - |
| Zembrace SymTouch | $11M | $9M | +24.2% |
| Tosymra | $2M | $1M | +86.2% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxytocin Small moleculeNCT07730294 | Pain | Phase 2 | NOT YET_RECRUITING | 75 | Aug 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every TNXP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TNX-1500 | prevention of kidney transplant rejection | Phase 1 | 2026-05-27 | blocked the primary T cell · dependent antibody response to KLH at all doses; blocked the secondary response at the 10 and 30 mg/kg doses; reduced peak secondary response to KLH by ~70% relative to placebo at the 3 mg/kg doseRead More | Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical ImmunologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LEDERMAN SETHDirector, Officer (Chief Executive Officer) | Buy | 2,000 11,005 held | $13.79 | 08/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TNXP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.1 % (-66.7 %) | 650.00 K | 1.10 M | -75.55% ( -3.40 M) |
TNXP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TNXP ranks across every disease it competes in
Competitive Position is a premium feature
See how TNXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTNXP News
TNXPTonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals has announced a significant managed Medicare agreement for its fibromyalgia treatment, TONMYA, which adds approximately 21 million Medicare lives to its coverage. This brings the total Medicare coverage to 32 million lives and overall payer coverage to 166 million lives in the U.S. The agreement is expected to enhance patient access and awareness of TONMYA, which is the first new treatment for fibromyalgia in over 15 years.
Read more →TNXPTonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Tonix Pharmaceuticals has promoted Thomas Englese to Chief Commercial Officer, effective immediately. Englese, who previously served as Executive Vice President of Commercial Operations, will oversee the sales and marketing of TONMYA, a new treatment for fibromyalgia. His leadership is expected to drive the company's growth and enhance patient access to their products.
Read more →TNXPTonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
Tonix Pharmaceuticals will participate in Cantor’s 2026 Global Healthcare Conference from September 9-11, 2026. CEO Seth Lederman will present during a fireside chat on September 10. The company focuses on CNS disorders, infectious diseases, and rare diseases, with several products in its pipeline, including TONMYA for fibromyalgia and TNX-4800 for Lyme disease prevention.
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals reported strong financial results for Q2 2026, with net sales of TONMYA reaching approximately $11 million, a 197% increase from the previous quarter. The company expanded its payer coverage to approximately 136 million lives and enrolled the first patient in its Phase 2 HORIZON study for major depressive disorder. Despite these successes, Tonix experienced a net loss of $40.6 million, reflecting increased operational costs.
Read more →TNXPTonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals announced its participation in two upcoming investor conferences in August and September 2026. CEO Seth Lederman will present at the Canaccord Genuity Annual Growth Conference and participate in 1x1 meetings at the Morgan Stanley Global Healthcare Conference. The company continues to focus on developing treatments for CNS disorders and other significant health challenges.
Read more →TNXP▲ +6.5%on this newsshared move
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Tonix Pharmaceuticals has received positive feedback from the FDA regarding the design of its adaptive Phase 2 study for TNX-4800, a monoclonal antibody aimed at preventing Lyme disease. The study is set to begin in early 2027 and will involve around 3,300 adult participants. TNX-4800 is designed to provide passive immunity and may offer advantages over existing vaccines.
Read more →TNXPTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Tonix Pharmaceuticals will report its second quarter 2026 financial results on August 10, 2026, during a conference call and webcast. The company is actively involved in developing treatments for CNS disorders, infectious diseases, and rare diseases. Key products include TONMYA for fibromyalgia and ongoing clinical studies for TNX-102 SL.
Read more →TNXPTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Tonix Pharmaceuticals has published research in the Journal of Virology demonstrating that the 2022 mpox outbreak strain (clade IIb) is significantly less virulent than the 2003 strain (clade IIa). The study introduces new animal models for studying mpox, which will support the development of TNX-801, a vaccine candidate aimed at preventing mpox and smallpox. This research highlights the urgent need to understand emerging mpox variants amid ongoing outbreaks.
Read more →TNXP▼ -6.6%on this newsshared move
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals has announced a significant managed Medicare agreement for its fibromyalgia treatment, TONMYA, effective January 1, 2027. This agreement will add approximately 9 million Medicare lives, enhancing the total pharmacy coverage to around 145 million lives. The company plans to expand its sales force to capitalize on this growth and improve patient access to TONMYA.
Read more →TNXPTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Tonix Pharmaceuticals has announced the enrollment of the first patient in the Phase 2 HORIZON study, which evaluates TNX-102 SL as a treatment for major depressive disorder (MDD). The study aims to assess the drug's efficacy in improving depressive symptoms and sleep quality. TNX-102 SL has previously shown positive signals in related conditions, suggesting its potential effectiveness for MDD.
Read more →TNXPTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Tonix Pharmaceuticals will participate in BTIG's Infectious Disease Day 2026, scheduled for June 16, 2026. CEO Seth Lederman will represent the company in virtual 1x1 meetings. Tonix is focused on CNS and immunology treatments, with several products in development, including TONMYA for fibromyalgia and others targeting Lyme disease and kidney transplant rejection.
Read more →TNXP▲ +5.8%on this newsshared move
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA , Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Tonix Pharmaceuticals has announced a new commercial payer agreement for its fibromyalgia treatment, TONMYA, effective from June 1, 2026. This agreement adds approximately 17 million U.S. commercial lives to its coverage, bringing the total to around 52 million lives, or 29% of the total commercial lives in the U.S. The company's CEO has emphasized the importance of this coverage in expanding patient access to TONMYA, which is notably the first new fibromyalgia treatment approved by the FDA in over 15 years. Additional initiatives and ongoing discussions are underway to further enhance access through Medicare and Medicaid channels.
Read more →TNXPTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA , Expanding Total Commercial Coverage to ~52 Million U.S. Lives with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional
Tonix Pharmaceuticals has announced a new agreement with a group purchasing organization, effective June 1, 2026, that expands coverage for its fibromyalgia treatment TONMYA to an additional 17 million U.S. commercial lives. This brings the total commercial coverage to approximately 52 million lives, amounting to about 29% of the total commercial lives in the U.S. The medication, which received FDA approval in August 2025, is notable for being the first new option for fibromyalgia in over 15 years. This expansion of coverage aims to enhance patient access as the company progresses with the commercial launch of TONMYA.
Read more →TNXPTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Tonix Pharmaceuticals presented a retrospective analysis at the 2026 ASCP Annual Meeting, revealing high opioid prescription rates among fibromyalgia patients, despite guidelines discouraging their use. The analysis included over 261,000 patients and highlighted the health burden of opioid use. Tonix also launched TONMYA, a new non-opioid treatment for fibromyalgia, emphasizing the need for better education on available therapies.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Tonix Pharmaceuticals has published Phase 1 clinical data for TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study demonstrated TNX-1500's safety and tolerability, with promising results in suppressing T cell-dependent antibody responses. A Phase 2 study is anticipated to begin in late 2026, pending FDA approval.
Read more →TNXPTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Tonix Pharmaceuticals presented findings at ISPOR 2026 from a real-world claims analysis of U.S. adults with fibromyalgia, utilizing over three years of closed claims data. The study revealed a high prevalence of comorbidities and extensive healthcare resource utilization among this patient demographic. Notably, Tonix launched TONMYA, the first new fibromyalgia treatment in more than 15 years. The data reinforce the complexities of managing fibromyalgia and the need for comprehensive approaches to improve patient outcomes.
Read more →TNXP▲ +11.7%on this news
Tonix Pharmaceuticals Holding Corp. TNX - 4800: A Long - Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S. Zeil Rosenberg MD, MPH Executive Vice President, Medical Tonix Pharmaceutical s
Tonix Pharmaceuticals Holding Corp. is presenting TNX-4800, a long-acting human monoclonal antibody aimed at preventing Lyme disease. This investigational biologic, which provides passive immunity, is designed to potentially block the transmission of Lyme disease from infected ticks. TNX-4800 is currently undergoing development, and its approval is contingent on successful clinical trials and compliance with regulatory standards. The company highlights the importance of addressing market competition and financial needs as they advance this innovative treatment.
Read more →TNXPTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026, focusing on a retrospective analysis of fibromyalgia patients using U.S. claims data. The study aims to characterize the patient population and enhance understanding of the condition. TONMYA, a recently approved treatment for fibromyalgia, represents a significant advancement in therapy options. The presentation will take place on May 20, 2026, in Philadelphia.
Read more →TNXPTonix Pharmaceuticals to Participate in Two Investor Conferences in May 2026
Tonix Pharmaceuticals announced participation in two investor conferences in May 2026. CEO Seth Lederman will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Conference. The company continues to focus on CNS and immunology treatments, with several products in development and ongoing clinical trials.
Read more →TNXP▼ -5.9%on this newsshared move
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals reported strong initial performance for its fibromyalgia treatment, TONMYA, with over 3,500 patients initiating treatment since its launch. The company signed a partnership to enhance access for millions of U.S. lives and plans to initiate a Phase 2 study for Lyme disease prevention. Despite a significant net loss this quarter, Tonix remains focused on advancing its clinical pipeline.
Read more →About Tonix Pharmaceuticals Holding Corp.
Headquarters200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922
BIOPHARMAWATCH ELITE PLUS
Trade the next TNXP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime